| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -74,723 | 47,726 |
| Proceeds from issuance of notes payable to related party, net of issuance costs paid | - | 0 |
| Proceeds from issuance of pre-merger oruka series a preferred stock, net of issuance costs paid | - | 0 |
| Proceeds from the pipe financings, net | 169,908 | - |
| Proceeds from issuance of common stock | 109 | 109 |
| Payment of deferred offering costs | - | 0 |
| Net cash provided by financing activities | 170,017 | 109 |
| Net increase in cash and cash equivalents | 29,678 | 3,821 |
| Cash and cash equivalents at beginning of period | 61,575 | - |
| Cash and cash equivalents at end of period | 91,253 | - |
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)